Christopher J Magnani1, Jecca R Steinberg1,2, Cécile I Harmange3, Xinyuan Zhang1, Conor Driscoll4, Alexander Bell5, Jeffrey Larson4, Jonathan G You1, Brannon T Weeks1, Tina Hernandez-Boussard6, Brandon E Turner1,7, James D Brooks8. 1. School of Medicine, Stanford University, Stanford, California. 2. Department of Obstetrics and Gynecology, Northwestern University, Chicago, Illinois. 3. School of Medicine, University of Colorado, Aurora, Colorado. 4. Feinberg School of Medicine, Northwestern University, Chicago, Illinois. 5. School of Medicine, UCSF, San Francisco, California. 6. Department of Medicine, School of Medicine, Stanford University, Stanford CA, USA. 7. Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts. 8. Department of Urology, Stanford University, Stanford, California.
Abstract
PURPOSE: Clinical trials require significant resources, but benefits are only realized after trial completion and dissemination of results. We comprehensively assessed early discontinuation, registry results reporting, and publication by trial sponsor and subspecialty in urology trials. MATERIALS AND METHODS: We assessed trial registrations from 2007 to 2019 on ClinicalTrials.gov and publication data from PubMed®/MEDLINE®. Associations between sponsor or subspecialty with early discontinuation were assessed using Cox proportional hazards and results reporting or publication with logistic regression at 3 years after completion. RESULTS: Of 8,636 trials 3,541 (41.0%) were completed and 999 (11.6%) were discontinued. Of completed trials 26.9% reported results and 21.6% were published. Sponsors included academic institutions (53.1%), industry (37.1%) and the U.S. government (9.8%). Academic-sponsored (adjusted HR 0.81, 95% CI 0.69-0.96, p=0.012) and government-sponsored trials (adjusted HR 0.62, 95% CI 0.49-0.78, p <0.001) were less likely than industry to discontinue early. Government-sponsored trials were more likely to report (adjusted OR 1.72, 95% CI 1.17-2.54, p=0.006) and publish (adjusted OR 1.89, 95% CI 1.23-2.89, p=0.004). Academic-sponsored trials were less likely to report (adjusted OR 0.65, CI:0.48-0.88, p=0.006) but more likely to publish (adjusted OR 1.72, 95% CI 1.25-2.37, p <0.001). These outcomes were similar across subspecialties. However, endourology was more likely to discontinue early (adjusted HR 2.00, 95% CI 1.53-2.95, p <0.001), general urology was more likely to report results (adjusted OR 1.54, 95% CI 1.13-2.11, p=0.006) and andrology was less likely to publish (adjusted OR 0.53, 95% CI 0.35-0.81, p=0.003). CONCLUSIONS: Sponsor type is significantly associated with trial completion and dissemination. Government-sponsored trials had the best performance, while industry and academic-sponsored trials lagged in completion and results reporting, respectively. Subspecialty played a lesser role. Lack of dissemination remains a problem for urology trials.
PURPOSE: Clinical trials require significant resources, but benefits are only realized after trial completion and dissemination of results. We comprehensively assessed early discontinuation, registry results reporting, and publication by trial sponsor and subspecialty in urology trials. MATERIALS AND METHODS: We assessed trial registrations from 2007 to 2019 on ClinicalTrials.gov and publication data from PubMed®/MEDLINE®. Associations between sponsor or subspecialty with early discontinuation were assessed using Cox proportional hazards and results reporting or publication with logistic regression at 3 years after completion. RESULTS: Of 8,636 trials 3,541 (41.0%) were completed and 999 (11.6%) were discontinued. Of completed trials 26.9% reported results and 21.6% were published. Sponsors included academic institutions (53.1%), industry (37.1%) and the U.S. government (9.8%). Academic-sponsored (adjusted HR 0.81, 95% CI 0.69-0.96, p=0.012) and government-sponsored trials (adjusted HR 0.62, 95% CI 0.49-0.78, p <0.001) were less likely than industry to discontinue early. Government-sponsored trials were more likely to report (adjusted OR 1.72, 95% CI 1.17-2.54, p=0.006) and publish (adjusted OR 1.89, 95% CI 1.23-2.89, p=0.004). Academic-sponsored trials were less likely to report (adjusted OR 0.65, CI:0.48-0.88, p=0.006) but more likely to publish (adjusted OR 1.72, 95% CI 1.25-2.37, p <0.001). These outcomes were similar across subspecialties. However, endourology was more likely to discontinue early (adjusted HR 2.00, 95% CI 1.53-2.95, p <0.001), general urology was more likely to report results (adjusted OR 1.54, 95% CI 1.13-2.11, p=0.006) and andrology was less likely to publish (adjusted OR 0.53, 95% CI 0.35-0.81, p=0.003). CONCLUSIONS: Sponsor type is significantly associated with trial completion and dissemination. Government-sponsored trials had the best performance, while industry and academic-sponsored trials lagged in completion and results reporting, respectively. Subspecialty played a lesser role. Lack of dissemination remains a problem for urology trials.
Entities:
Keywords:
clinical trials as topic; randomized controlled trials as topic; research support as topic
Authors: Xu Liu; Yuan Zhang; Ling-Long Tang; Quynh Thu Le; Melvin L K Chua; Joseph T S Wee; Nancy Y Lee; Brian O'Sullivan; Anne W M Lee; Ying Sun; Jun Ma Journal: JAMA Oncol Date: 2018-08-01 Impact factor: 31.777
Authors: Jathin Bandari; Katherine M Theisen; Avinash Maganty; Benjamin J Davies; Jonathan G Yabes; Bruce L Jacobs Journal: J Urol Date: 2020-04-07 Impact factor: 7.450
Authors: Emily M Rencsok; Latifa A Bazzi; Rana R McKay; Franklin W Huang; Adam Friedant; Jake Vinson; Samuel Peisch; Jelani C Zarif; Stacey Simmons; Kelly Hawthorne; Paul Villanti; Philip W Kantoff; Elisabeth Heath; Daniel J George; Lorelei A Mucci Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-06-05 Impact factor: 4.254
Authors: Chris Stockmann; Catherine M T Sherwin; Gideon Koren; Sarah C Campbell; Jonathan E Constance; Matthew Linakis; Alfred Balch; Michael W Varner; Michael G Spigarelli Journal: J Clin Pharmacol Date: 2013-11-14 Impact factor: 3.126
Authors: Jecca R Steinberg; Brandon E Turner; Brannon T Weeks; Christopher J Magnani; Bonnie O Wong; Fatima Rodriguez; Lynn M Yee; Mark R Cullen Journal: JAMA Netw Open Date: 2021-06-01